Mortality and inpatient hospitalizations by anti-plasma cell dyscrasia treatment patterns among patients with cardiac light chain amyloidosis: results from a US administrative claims database

Aim: To gain insights into real-world mortality and hospitalization among newly diagnosed patients with light chain (AL) amyloidosis initiating anti-plasma cell dyscrasia treatment. Materials & methods: This retrospective, noninterventional, observational study evaluated real-world mortality by treatment patterns and hospitalization among adult patients newly diagnosed with AL amyloidosis with cardiomyopathy in the US IQVIA PharMetrics claims database. Data from treatment initiation (index date) to 365 days postindex were evaluated. Patients receiving treatments for AL amyloidosis in the year prior to the index date were excluded. AL-, cardiac-, and cardiac/renal-related healthcare resource utilization were assigned using the International Classification of Diseases, Tenth Revision . Summary statistics are reported by cardiac or cardiac/renal involvement. Results: A total of 198 patients with cardiac AL amyloidosis were included in this study (mean age, 64.8 years; 70.7% male). The 1-year mortality and condition-related hospitalization rates among all patients were 9.1% (18 of 198) and 65.7% (130 of 198), respectively. Daratumumab was prescribed for 138 (69.7%) patients, with 1-year mortality and condition-related hospitalization rates of 7.2% (10 of 138) and 67.4% (93 of 138), respectively. Daratumumab was not prescribed for 60 (30.3%) patients, with 1-year mortality and condition-related hospitalization rates of 13.3% (8 of 60) and 61.7% (37 of 60), respectively. One-year mortality and condition-related hospitalization rates among patients with only cardiac involvement (n = 66) were 7.6% (5 of 66) and 45.5% (30 of 66), respectively, and 9.8% (13 of 132) and 75.8% (100 of 132), respectively, among patients with cardiac and renal involvement (n = 132). Conclusion: Treatment patterns varied considerably among patients with AL amyloidosis. Mortality and hospitalizations were higher among patients with both cardiac and renal involvement than among those with only cardiac involvement.

Authors

Institutions

Publication Details

Journal
Journal of Comparative Effectiveness Research
Published
2026-11-17
DOI
https://doi.org/10.57264/cer-2026-0104
Primary Topic
Amyloidosis: Diagnosis, Treatment, Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Mortality and inpatient hospitalizations by anti-plasma cell dyscrasia treatment patterns among patients with cardiac light chain amyloidosis: results from a US administrative claims database

Jeffrey E. Thompson, Julia Catini, Clifton Chow
5 links
Journal of Comparative Effectiveness Research
Amyloidosis: Diagnosis, Treatment, Outcomes
article

Mortality and inpatient hospitalizations by anti-plasma cell dyscrasia treatment patterns among patients with cardiac light chain amyloidosis: results from a US administrative claims database

Jeffrey E. Thompson, Julia Catini, Clifton Chow
article en

Abstract

Aim: To gain insights into real-world mortality and hospitalization among newly diagnosed patients with light chain (AL) amyloidosis initiating anti-plasma cell dyscrasia treatment. Materials & methods: This retrospective, noninterventional, observational study evaluated real-world mortality by treatment patterns and hospitalization among adult patients newly diagnosed with AL amyloidosis with cardiomyopathy in the US IQVIA PharMetrics claims database. Data from treatment initiation (index date) to 365 days postindex were evaluated. Patients receiving treatments for AL amyloidosis in the year prior to the index date were excluded. AL-, cardiac-, and cardiac/renal-related healthcare resource utilization were assigned using the International Classification of Diseases, Tenth Revision . Summary statistics are reported by cardiac or cardiac/renal involvement. Results: A total of 198 patients with cardiac AL amyloidosis were included in this study (mean age, 64.8 years; 70.7% male). The 1-year mortality and condition-related hospitalization rates among all patients were 9.1% (18 of 198) and 65.7% (130 of 198), respectively. Daratumumab was prescribed for 138 (69.7%) patients, with 1-year mortality and condition-related hospitalization rates of 7.2% (10 of 138) and 67.4% (93 of 138), respectively. Daratumumab was not prescribed for 60 (30.3%) patients, with 1-year mortality and condition-related hospitalization rates of 13.3% (8 of 60) and 61.7% (37 of 60), respectively. One-year mortality and condition-related hospitalization rates among patients with only cardiac involvement (n = 66) were 7.6% (5 of 66) and 45.5% (30 of 66), respectively, and 9.8% (13 of 132) and 75.8% (100 of 132), respectively, among patients with cardiac and renal involvement (n = 132). Conclusion: Treatment patterns varied considerably among patients with AL amyloidosis. Mortality and hospitalizations were higher among patients with both cardiac and renal involvement than among those with only cardiac involvement.

Journal of Comparative Effectiveness Research
Harvard University (US), AstraZeneca (United States) (US)
Good health and well-being
Amyloidosis: Diagnosis, Treatment, Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon